http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#Head http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#assertion http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#provenance http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#pubinfo http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#assertion http://purl.obolibrary.org/obo/DOID_1926 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_1926 http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB09039 http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#association http://www.w3.org/2000/01/rdf-schema#label cerdelga is indicated for the long term treatment of adult patients with gaucher disease type 1 gd1 who are cyp2d6 extensive metabolizers ems intermediate metabolizers ims or poor metabolizers pms as detected by an fda cleared test see dosage and administration 2 1 cerdelga is a glucosylceramide synthase inhibitor indicated for the long term treatment of adult patients with gaucher disease type 1 who are cyp2d6 extensive metabolizers ems intermediate metabolizers ims or poor metabolizers pms as detected by an fda cleared test 1 limitations of use cyp2d6 ultra rapid metabolizers may not achieve adequate concentrations of cerdelga to achieve a therapeutic effect 1 a specific dosage cannot be recommended for cyp2d6 indeterminate metabolizers 1 limitations of use patients who are cyp2d6 ultra rapid metabolizers urms may not achieve adequate concentrations of cerdelga to achieve a therapeutic effect see clinical studies 14 a specific dosage cannot be recommended for those patients whose cyp2d6 genotype cannot be determined indeterminate metabolizers see clinical studies 14 http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB09039 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#provenance http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#pubinfo http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#sig http://purl.org/nanopub/x/hasSignature ETYCD+lirERQF6b0Ei6c6patvEaJ9gFUT+twB6KJmuH22oOL5L4gPyH1dr8AlkH0cpgLmmS+3ETBypfg4UhEKVBPVJ+dvSApBSa4po6WF7VI4BCSa+s2AfHwJQKxo2/wY32tV9erK/V/wwzt1vSIerAJz1gE78DgvqJU+A8hxqs= http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4 http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4 http://purl.org/dc/terms/created 2021-06-12T14:23:10.024+02:00 http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs